Johnson & Johnson Amendment to Schedule 13G for Rapport Therapeutics

Johnson & Johnson and its subsidiary Johnson & Johnson Innovation-JJDC, Inc. have filed Amendment No. 1 to Schedule 13G, reporting their ownership of 1,784,517 shares of Common Stock in Rapport Therapeutics, Inc., representing 4.9% ownership. The filing indicates a decrease of 713,534 shares compared to the previous report, reflecting a 28.56% reduction in shares held. The amendment is filed under Rule 13d-1(d) and updates the ownership details as of September 30, 2025. The filing is significant as it reflects changes in the ownership structure of Rapport Therapeutics by a major healthcare corporation.